Roflumilast augmente le signal cAMP de Semaglutide, étendant la suppression de l'appétit

In mice, blocking the cAMP‑degrading enzyme PDE4 with the drug roflumilast kept semaglutide‑induced cAMP levels elevated in area postrema neurons, hinting that GLP‑1 therapy could last longer with fewer injections.

cAMP Dynamics in the Area Postrema

Semaglutide, a GLP‑1 receptor agonist, triggers a rise in cyclic adenosine monophosphate inside neurons of the area postrema, a brainstem region that governs appetite. Using two‑photon fluorescence imaging, Gao et al. observed that the magnitude of cAMP responses varied across individual cells, forming a continuum rather than a binary switch. Some neurons sustained high cAMP for hours, while others showed transient spikes that faded as GLP‑1 receptors were internalized or degraded.

PDE4 Inhibition as a Potentiator

The team selectively knocked down PDE4, the phosphodiesterase that hydrolyzes cAMP, and treated slices with roflumilast, a clinically approved PDE4 inhibitor. This manipulation shifted the population of neurons toward the sustained‑response phenotype, effectively amplifying the duration of the semaglutide signal. The result was a measurable extension of the appetite‑suppressing window in the brain, suggesting that PDE4 blockade could reduce the need for frequent dosing.

Clinical Implications and Next Steps

If the same mechanism translates to humans, patients on semaglutide or other GLP‑1 drugs might achieve longer weight‑loss effects with a single dose, potentially improving adherence and reducing side‑effects. The authors caution that current imaging techniques only capture hours of intracellular activity; future work will need to monitor cAMP dynamics over days or weeks in vivo. Additionally, the safety profile of chronic PDE4 inhibition in obese patients remains to be established.

These findings open a path toward combination therapies that sustain GLP‑1 signaling, offering a tangible strategy to overcome the plateau that plagues many weight‑loss regimens.

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov